HDAC2 Inhibition Amplifies Oxytocin Signaling, Boosting Neuroprotection in Female Stroke Mice

Effective neuroprotective treatments for ischemic stroke remain elusive, partly due to the continuous failure to account for biological sex differences in research and clinical trials. While epigenetic modulators, such as HDAC inhibitors, show promise, the precise mechanisms underlying their sexually dimorphic effects are largely unknown. This knowledge gap impedes the development of truly individualized therapies, despite evidence of inherent sex-divergent neuroprotective pathways that could be leveraged.

Researchers investigated HDAC2 as a critical epigenetic brake on endogenous neuroprotective mechanisms in ischemic stroke models using female mice. The study aimed to uncover how HDAC2 inhibition modulates these pathways, specifically focusing on sex-divergent responses and the role of oxytocin signaling. They likely employed in vivo models to assess neuroprotection and stroke recovery, alongside molecular assays to analyze changes in gene expression and signaling pathways related to oxytocin and estrogen.

The study revealed that HDAC2 acts as a critical epigenetic brake on a built-in neuroprotective mechanism. When HDAC2 is inhibited, this mechanism is activated, leading to a therapeutically potent, sex-divergent response. Specifically, this activation amplifies estrogen-driven oxytocin signaling, which was found to confer superior neuroprotection in female mice models of ischemic stroke. The findings highlight HDAC2 as a druggable epigenetic target capable of modulating intrinsic brain resilience in a sex-specific manner. > This epigenetic switch defines a path toward individualized stroke therapy by leveraging enhanced oxytocin signaling, particularly in females, for superior neuroprotection.